22021 20th Avenue SE
About AGC Biologics
AGC Biologics is a global contract process development and manufacturer of biopharmaceuticals. We offer our clients a full suite of contract services from DNA to API and leverage our technical expertise to transform these services into solutions that meet our clients’ near- and long-term objectives. With cGMP compliant facilities in both the United States and Europe and a team of more than 500 dedicated employees, every project is performed with our absolute commitment to quality manufacturing and customer satisfaction.
While our efforts touch a defined part of the expansive drug development and commercialization continuum, we see ourselves as partners in our clients’ success bringing products to patients. AGC Biologics has become our clients’ manufacturing partner of choice because they trust us to make their needs and objectives our own.
61 articles with AGC Biologics
New facility will include comprehensive mammalian process development and manufacturing capabilities
Strategic expansion will meet increasing global demand for biopharmaceutical development and manufacturing.
Ribbon Cutting Ceremony Held to Commemorate Company Milestone
AGC Biologics announced the company will participate in the upcoming BIO International Convention in Boston, Mass. on June 4-7, 2018.
Drug Substance produced in AGC Biologics' facility in Bothell, Washington
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered into a commercial supply agreement with MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.
AGC Biologics announced it has entered into an agreement with Horizon Pharma plc for commercial supply of teprotumumab.
Jin Wang, Ph.D. named Site Head/General Manager
Addition of new facilities supports strong company-wide growth initiative
Axel Schleyer, Ph.D. named Senior Vice President of Business Development, North America; Christoph Winterhalter, Ph.D. named Senior Vice President of Business Development, Europe
AGC Biologics, a convergence of Asahi Glass Company Bioscience, Biomeva GmbH, and CMC Biologics , announced today that effective January 8, 2018, the company will be integrated and newly branded as AGC Biologics.
CMC Biologics and Harpoon Therapeutics announced today they have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC molecules for the treatment of various human cancers.
Altor BioScience Corporation And CMC Biologics Announce Agreement For Manufacture And Validation Of Altor's IL-15 Superagonist Molecule, ALT-803, For Use In Phase III Clinical Trials
Through Their PROVEO Partnership, CMC Biologics And IDT Biologika Announce The Addition Of Cerbios-Pharma And Oncotec Pharma To Their Strategic Collaboration For Manufacture Of Antibody Drug Conjugates